NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
+1.82%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$1.3B
AUM Growth
+$1.3B
(-27%)
Cap. Flow
-$454M
Cap. Flow
% of AUM
-34.94%
Top 10 Holdings %
Top 10 Hldgs %
80.36%
Holding
42
New
–
Increased
2
Reduced
3
Closed
4
Top Buys
| 1 |
Senti Biosciences
SNTI
|
$11.2M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$3.51M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$184M |
| 2 |
TEM
Tempus AI, Inc. Class A Common Stock
TEM
|
$134M |
| 3 |
NextNav
NN
|
$127M |
| 4 |
Geron
GERN
|
$9.83M |
| 5 |
Sagimet Biosciences
SGMT
|
$9M |
Sector Composition
| 1 | Healthcare | 92.44% |
| 2 | Consumer Staples | 6.6% |
| 3 | Industrials | 0.55% |
| 4 | Communication Services | 0.41% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $246M | 18.92% | 3,745,262 | – | – |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $171M | 13.15% | 2,688,565 -2,896,188 | -52% | -$184M |
|
3
Rhythm Pharmaceuticals
RYTM
$6.85B
| $154M | 11.87% | 2,909,956 | – | – |
|
|
TEM
4
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $126M | 9.72% | 2,615,979 -2,770,000 | -51% | -$134M |
|
5
Coursera
COUR
$1.88B
| $85.7M | 6.6% | 12,867,769 | – | – |
|
6
Trevi Therapeutics
TRVI
$883M
| $71.5M | 5.51% | 11,370,376 | – | – |
|
7
Savara
SVRA
$567M
| $67.8M | 5.22% | 24,471,264 | – | – |
|
8
CRISPR Therapeutics
CRSP
$4.71B
| $54M | 4.16% | 1,587,854 | – | – |
|
9
Monte Rosa Therapeutics
GLUE
$296M
| $35.7M | 2.75% | 7,692,298 | – | – |
|
10
Aurinia Pharmaceuticals
AUPH
$1.58B
| $31.9M | 2.46% | 3,969,834 | – | – |
|
|
MBX
11
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $26.7M | 2.05% | 3,614,486 | – | – |
|
12
CVRx
CVRX
$205M
| $24.8M | 1.91% | 2,026,083 | – | – |
|
|
ZBIO
13
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $20.7M | 1.59% | 2,613,948 | – | – |
|
14
Gossamer Bio
GOSS
$562M
| $19.9M | 1.53% | 18,093,034 | – | – |
|
15
Korro Bio
KRRO
$217M
| $19M | 1.46% | 1,090,793 | – | – |
|
16
NeueHealth
NEUE
$59.2M
| $18.4M | 1.42% | 2,726,917 | – | – |
|
17
Champions Oncology
CSBR
$93.8M
| $14.9M | 1.15% | 1,713,720 | – | – |
|
|
18
Senti Biosciences
SNTI
$38.5M
| $12.7M | 0.98% | 3,775,615 +3,333,000 | +753% | +$11.2M |
|
19
Celcuity
CELC
$2.17B
| $12.6M | 0.97% | 1,250,001 | – | – |
|
20
Phathom Pharmaceuticals
PHAT
$864M
| $12.3M | 0.95% | 1,960,169 | – | – |
|
|
21
Oric Pharmaceuticals
ORIC
$994M
| $12.3M | 0.94% | 2,195,545 +629,464 | +40% | +$3.51M |
|
|
RGLS
22
DELISTED
Regulus Therapeutics
RGLS
| $11.3M | 0.87% | 6,467,802 | – | – |
|
|
DM
23
DELISTED
Desktop Metal, Inc.
DM
| $7.07M | 0.54% | 1,439,892 | – | – |
|
24
Black Diamond Therapeutics
BDTX
$157M
| $6.9M | 0.53% | 4,448,757 | – | – |
|
25
Nkarta
NKTX
$151M
| $6.57M | 0.51% | 3,568,781 | – | – |
|